Glossary
Pulmonary hypertension
This isn't the blood pressure measured on your arm, and the difference is the point of the page. It's a different circuit that needs different tests. It gets screened for on purpose, because by the time it announces itself the early window has usually closed.
What the research found.
One nationwide Korean study reviewed 751 people with systemic sclerosis and counted their organ problems. Lung scarring was the commonest organ problem at 52.7 percent, reflux came next at 32.9 percent, and pulmonary arterial hypertension affected 13.6 percent. Five-year survival was 94 percent and ten-year survival was 87 percent.
Moon and colleagues, Journal of Korean Medical Science, 2018
One study followed 310 people with lupus-associated pulmonary arterial hypertension. Survival was 92.1 percent at one year, 84.8 percent at three, and 72.9 percent at five. Reaching the treatment goal predicted survival, and the share who had reached it rose from 31.5 percent to 62.7 percent over that period.
One study followed 411 people for a median of 3.5 years. Meeting one low-risk mark at six months gave a hazard ratio of 0.65 for death or transplant, meeting two gave 0.45, and meeting all three gave 0.32. The true value for all three sits from 0.21 to 0.52.
One German study followed 3257 people with systemic sclerosis and tracked their lungs over time. By the end, 47.6 percent had lung scarring, 15.2 percent had it alongside pulmonary hypertension, and 6.5 percent had pulmonary arterial hypertension. Five-year survival was 96.4 percent in those with no lung involvement at all.
What it is
Pulmonary hypertension is high blood pressure in the arteries that take blood from your heart to your lungs. The name is a good deal longer than the idea behind it. It means one particular circuit in your body is under too much pressure, and it isn't the circuit anybody usually means.
That's a different circuit from the one a cuff on your arm measures. The left side of your heart pumps blood out to your body, and the right side pumps it to your lungs to pick up oxygen. This page is about a problem in the second of those two loops.
When pressure rises in the lung arteries, the right side of the heart has to push harder against it. Over time that side of the heart begins to struggle. That's the mechanism behind everything else on this page, and it's the reason the numbers look the way they do.
Why your arm cuff can't find it
The two circuits don't move together, and that's the practical heart of this section. Your body-side pressure can sit perfectly normal while the lung-side pressure is high. That isn't a quirk of measurement, because the two are separated by the whole of your lungs and by two different pumping chambers.
Nothing about one of them predicts what the other is doing. So this needs its own tests entirely, and that's the main practical thing to take away. It explains why a normal blood pressure reading isn't the reassurance it sounds like when somebody reads it out to you.
Why it gets looked for
There are two reasons, and the second one is what counts. The first is that it's commoner in these illnesses than in the general population. One nationwide Korean study reviewed 751 people with systemic sclerosis, where pulmonary arterial hypertension affected 13.6 percent of them, behind lung scarring at 52.7 percent and reflux at 32.9 percent.
The second reason is that its early symptoms hide inside the illness you already have. Breathlessness and tiredness describe a great many people with rheumatic disease. So waiting for symptoms to declare themselves doesn't work here, because the symptoms are already there for other reasons entirely.
A German study shows it can come early rather than late. It followed 3257 people with systemic sclerosis, and at the start 4.5 percent had pulmonary hypertension with no lung scarring at all. So this isn't only a late complication of a lung already damaged.
What the figures say
These are serious numbers, and it's better to have them than to guess at them. Read the next section as well as this one, because the two belong together. One study followed 310 people with lupus-associated pulmonary arterial hypertension, where survival was 92.1 percent at one year, 84.8 percent at three years, and 72.9 percent at five.
The German study gives a comparison worth setting beside those. Among those with no lung involvement at all, five-year survival was 96.4 percent. Survival differed significantly across the groups, and it was worst in those with both lung scarring and pulmonary hypertension together.
Three things in that study went with lower death rates. Being female came with a hazard ratio of 0.3, a higher body mass index with 0.9, and better gas transfer on lung testing with 0.98. That last one is the measure a clinic can follow over time.
Does the cause change the outlook
Two studies here disagree, and the disagreement is worth seeing rather than smoothing over. Both are on file and both look sound. One followed 102 people admitted to intensive care, where one-year survival was 51.4 percent when a connective tissue disease was the cause and 79.8 percent when it wasn't, at a log-rank P value of 0.019.
One compared outpatients instead, and got a very different answer. Survival at one, three, and five years was 97, 76, and 55 percent for the connective tissue group, against 93, 77, and 54 percent for the idiopathic group, at P equals 0.884. Those two sets of numbers are effectively identical.
The populations explain a good deal of that. The first study looked only at people sick enough to need intensive care, while the second looked at people being followed in an ordinary clinic. So the honest summary is that the cause may count for more when things are going badly than when they aren't.
One finding from the outpatient study is worth keeping. Of seven other illnesses examined, only chronic kidney disease predicted a worse outcome after adjustment, at a hazard ratio of 1.83 from 1.19 to 2.80. It did so whatever the cause of the hypertension was.
The numbers that move
This is the part to take away, because it's the part that isn't fixed. Everything above describes groups, and this describes what changes. One study followed 411 people for a median of 3.5 years, counted how many low-risk marks each person met at six months, and then looked at what happened afterwards.
Meeting one gave a hazard ratio of 0.65 for death or transplant, from 0.46 to 0.92. Meeting two gave 0.45, from 0.31 to 0.66, and meeting all three gave 0.32, from 0.21 to 0.52. That's a stepwise fall rather than a single threshold, which is part of why each of the three marks is worth having even when all three are out of reach.
That study also gives a sense of the scale of change involved. At six months the average drop in a heart strain blood marker was 808, and the average rise in six-minute walk distance was 44 meters. Those are the kinds of numbers a clinic watches between appointments.
The lupus study makes that point from another angle entirely. The share of people who had reached the treatment goal rose from 31.5 percent at one year to 53.6 percent at three and 62.7 percent at five. Reaching that goal was itself a positive predictor of survival.
So ask your team what target they're aiming at, and ask whether you've reached it. Those are specific questions and fair ones to put. They're also the questions this page's evidence supports, which is more than most questions get.
Treatment aimed at the disease
One study suggests something useful about treating the underlying illness harder in some cases. The effect showed on pressure measures and on survival alike. It followed 141 people in Japan, all of whom had pulmonary arterial hypertension alongside a connective tissue disease other than systemic sclerosis.
Most had lupus, mixed connective tissue disease, or Sjogren's syndrome. Within three months, 57 of them started or stepped up immune-suppressing treatment. Over twelve months they improved more on two pressure measures, at P equals 0.032 and P equals 0.028, and deaths from any cause fell, at P equals 0.039. Deaths related to the hypertension fell as well, at P equals 0.020, while deaths from infection or cancer didn't differ between the groups.
Read that with one caution the authors supply themselves. The treated group was younger, had better kidney function, and had higher plasma IgG at the start. Those differences could produce some of the result on their own, which is why this is a lead rather than a conclusion.
What to report
The point of screening is to find this before it announces itself, and what you notice still counts. Some of the things on this list are easy to explain away. New or worsening breathlessness is the main one, and that goes double on stairs or slopes.
Getting tired far faster than you used to belongs there as well. Fainting or nearly fainting is worth reporting straight away rather than waiting for your next appointment. Swelling in your ankles or legs belongs on the list too, and so does chest tightness on effort.
None of those on its own means you have this, and most of them will turn out to be something else. All of them are worth raising rather than filing away, which is the whole message of this section. The people looking after you would much rather hear about it early than late.
Common misconceptions.
Myth. It's just high blood pressure by another name.
Reality. It's a different circuit altogether, which is why the two get measured differently. The pressure on your arm cuff is in the arteries feeding your body, while this is the pressure in the arteries feeding your lungs, which the right side of your heart pumps into. The two don't track each other, so a normal cuff reading tells you nothing about this.
Myth. There'd be obvious symptoms.
Reality. The early symptoms are breathlessness and tiredness, and almost everybody with a rheumatic disease has those already. That overlap is why it gets screened for rather than waited for. One German study followed 3257 people, and at the start 4.5 percent had pulmonary hypertension with no lung scarring, so it can be the first lung problem rather than a late one.
Myth. The survival figures mean nothing can be done.
Reality. The figures move with what happens next, and two studies show it. One of 411 people found that meeting all three low-risk marks at six months gave a hazard ratio of 0.32 for death or transplant, from 0.21 to 0.52. One of 310 people with lupus-related disease found reaching the treatment goal itself predicted survival, so the target is worth asking about directly.
Myth. It's only a problem in scleroderma.
Reality. Scleroderma is where it's commonest and it isn't the only place it turns up. One registry of 2196 people found 26.5 percent had a connective tissue disease as the cause. One study of 141 people covered disease linked to lupus, mixed connective tissue disease, and Sjogren's, and one study of 310 covered lupus on its own.
Myth. Once it's found, the diagnosis says everything.
Reality. The cause changes the outlook, though the evidence on that is split. One study of 102 people admitted to intensive care found one-year survival of 51.4 percent when a connective tissue disease was the cause, against 79.8 percent when it wasn't, at a log-rank P value of 0.019. Another study found the two groups almost level at five years, and that disagreement is worth knowing about.
Related terms.
- Systemic sclerosis, where this is commonest.
- Lupus, the other illness with a large study behind it here.
- Systemic sclerosis and exercise, for what the lung findings mean for activity.
Questions patients ask.
What is pulmonary hypertension?
High blood pressure in the arteries taking blood from your heart to your lungs. That's a separate circuit from the one measured on your arm, and the right side of the heart pumps into it. When the pressure there rises, that side of the heart has to work harder against it. Over time it struggles, which is where most of the trouble comes from.
Why isn't my arm cuff enough?
Because your arm cuff measures the wrong circuit for this particular question. The cuff reads the arteries feeding your body, which your left heart pumps into, while this is the lung circuit, fed by the right heart. The two of them don't move together, and nothing about one predicts the other. A perfectly normal cuff reading is entirely compatible with high pressure on the lung side.
Why do they look for it in rheumatic disease?
Two reasons, and the second one is what makes screening worth doing. It's commoner in these illnesses than in the general population, and its early signs hide inside the illness you already have. Feeling short of breath and worn out fits most of these diseases. One Korean study followed 751 people with systemic sclerosis, and it found pulmonary arterial hypertension in 13.6 percent of them.
How common is it?
That depends a good deal on which illness you have. One Korean study of 751 people with systemic sclerosis found it in 13.6 percent of them. One German study followed 3257 people, and by the end 6.5 percent had pulmonary arterial hypertension, with another 15.2 percent having pulmonary hypertension alongside lung scarring. It turns up less often in the other rheumatic diseases on this site.
What do the survival figures look like?
They're serious, and they vary by what caused the problem. One study followed 310 people with lupus-related disease, where survival was 92.1 percent at one year, 84.8 percent at three years, and 72.9 percent at five. Another study compared connective tissue disease against idiopathic disease and found five-year survival of 55 percent against 54 percent, at P equals 0.884.
Does treatment change the outlook?
The evidence here says the numbers move rather than sitting still. One study of 411 people looked at low-risk marks measured at six months, where meeting one gave a hazard ratio of 0.65 for death or transplant, meeting two gave 0.45, and meeting all three gave 0.32, from 0.21 to 0.52. Ask your team which marks they're aiming at.
Does the cause change the treatment?
It appears to for some causes, on one registry at least. One Japanese registry followed 141 people whose disease came with a connective tissue illness other than scleroderma. The 57 who started or stepped up immune-suppressing treatment early improved more on two pressure measures, at P equals 0.032 and 0.028, and deaths fell too, at P equals 0.039.
What should I report?
New or worsening breathlessness, above all on stairs or slopes. Getting tired far faster than you used to belongs on the list, and so do fainting, near-fainting, swelling in your ankles or legs, and chest tightness on effort. Those are worth raising rather than filing away. The point of screening is catching this before it announces itself, and what you notice is part of that.
References.
- Moon KW; Lee SS; Lee YJ et al. Clinical and Laboratory Characteristics and Mortality in Korean Patients with Systemic Sclerosis: A Nationwide Multicenter Retrospective Cohort Study. J Rheumatol. 2018;45:1281-1288. 10.3899/jrheum.171443Journal Article
- Qian J; Li M; Zhang X et al. Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study. Eur Respir J. 2019;53. 10.1183/13993003.00081-2018Multicentre prospective cohort
- Hjalmarsson C; Thakur T; Weiss T et al. Risk assessment models and survival in pulmonary arterial hypertension: A SPAHR analysis. J Heart Lung Transplant. 2025;44:1787-1797. 10.1016/j.healun.2024.10.029Multicentre analysis of the Swedish Pulmonary Arterial Hypertension and CTEPH Registry
- Moinzadeh P; Bonella F; Oberste M et al. Impact of Systemic Sclerosis-Associated Interstitial Lung Disease With and Without Pulmonary Hypertension on Survival: A Large Cohort Study of the German Network for Systemic Sclerosis. Chest. 2024;165:132-145. 10.1016/j.chest.2023.08.013Large cohort study of the German Network for Systemic Sclerosis registry
- Naranjo M; Mercurio V; Hassan H et al. Causes and outcomes of ICU hospitalisations in patients with pulmonary arterial hypertension. ERJ Open Res. 2022;8. 10.1183/23120541.00002-2022Analysis of patients in a hospital pulmonary hypertension registry admitted to intensive care between January 2010 and December 2020
- Tamura Y; Tamura Y; Takemura R et al. Immunosuppressive Therapy for Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases: Insights from Japanese Registry. Adv Ther. 2025;42:6103-6117. 10.1007/s12325-025-03389-zMulticentre analysis of the Japan Pulmonary Hypertension Registry
- Bravo-Marqués R; Rivas-Ruiz F; Tenes A et al. New phenotype and outcomes in connective tissue disease-associated pulmonary arterial hypertension: relevance of age-related comorbidities. Rheumatology (Oxford). 2026;65. 10.1093/rheumatology/keag105Retrospective cohort from the Spanish Registry of Pulmonary Arterial Hypertension
- Huang X; Balasubramanian A; Moutchia J et al. Ambient Air Pollution Exposure and Mortality in the Pulmonary Hypertension Association Registry. Ann Am Thorac Soc. 2025;22:1351-1360. 10.1513/AnnalsATS.202501-129OCCohort of 2196 adults enrolled in the Pulmonary Hypertension Association Registry between 2015 and 2024
- Osgueritchian R; Jani VP; Mombeini H et al. Refining Risk Prediction in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. J Am Soc Echocardiogr. 2025;38:1064-1074. 10.1016/j.echo.2025.07.013Retrospective analysis of 174 patients with systemic sclerosis-associated pulmonary arterial hypertension from a scleroderma registry who had echocardiography within 6 months of invasive confirmation
This page gathers the published research on this subject into one place. The studies behind it were published between 1989 and 2026, and every figure links to the paper it came from. Those studies were peer reviewed. This summary of them was not. Dr. Sarah Luebker is reviewing these pages one at a time and has not reached this one yet, so it carries no medical review date and nothing here is her opinion or her advice to you. Each page gets updated as she reaches it. It is here in the meantime because the science is worth having in one organized place that is easy to find and easy to read. Talk to your own clinician before acting on any of it.